SELLAS Life Sciences Group (SLS) Expected to Post Earnings on Thursday

SELLAS Life Sciences Group (NASDAQ:SLS) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect SELLAS Life Sciences Group to post earnings of ($0.0450) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

SELLAS Life Sciences Group Stock Performance

Shares of SLS stock traded up $0.25 on Tuesday, hitting $11.47. 2,186,950 shares of the stock traded hands, compared to its average volume of 8,386,664. The stock has a market capitalization of $2.25 billion, a PE ratio of -49.86 and a beta of 2.48. The firm’s 50-day moving average price is $10.67 and its two-hundred day moving average price is $6.93. SELLAS Life Sciences Group has a twelve month low of $1.39 and a twelve month high of $15.88.

Institutional Trading of SELLAS Life Sciences Group

A number of hedge funds and other institutional investors have recently made changes to their positions in SLS. Geode Capital Management LLC increased its position in SELLAS Life Sciences Group by 168.2% during the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock worth $4,819,000 after buying an additional 1,379,988 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $136,000. Rhumbline Advisers acquired a new stake in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $297,000. XTX Topco Ltd purchased a new position in shares of SELLAS Life Sciences Group during the second quarter worth approximately $168,000. Finally, New York State Common Retirement Fund purchased a new position in shares of SELLAS Life Sciences Group during the second quarter worth approximately $108,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on SLS shares. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, SELLAS Life Sciences Group presently has an average rating of “Hold” and a consensus price target of $10.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.